Maria Luisa Sulis, MD, MS
Pediatric Hematologist-Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Pediatric Acute and Chronic Leukemias
- Pediatric Lymphoma
- Histiocytosis
About Me
- Chief, Pediatric Hematologic Malignancies Service
As a pediatric oncologist on the MSK Kids team, I am privileged to care for children with blood cancer. Most children with blood cancer today are cured, thanks to decades of collaboration among children’s cancer specialists around the world. However, the cure rate for children with cancer that does not respond to conventional therapy is still too low.
My research focuses on acute leukemia resistant to conventional therapies. My colleagues and I hope to use the advances we make in our understanding of the biology of leukemia and how patients respond to therapy to improve the effectiveness of children’s cancer treatment. I enjoy working closely with laboratory scientists, hematopathologists, and bioinformaticians. I strongly believe in two-way interaction. By bringing challenging questions to the laboratory, and making new diagnostic and treatment discoveries, we can cure more children with blood cancer while limiting the side effects of therapy.
Read more
I work closely with investigators in the Children’s Oncology Group (COG) and other collaborative groups to design clinical trials of new treatments for children with high-risk disease. For COG, I develop studies for children with newly diagnosed and relapsed T cell acute lymphoblastic leukemia. We study how to prevent a relapse of acute myeloid leukemia after a stem cell transplant.
Within MSK Kids, I oversee the clinical program for children with blood disorders. I work with an experienced and talented group of doctors, nurses, nurse practitioners, child life specialists, care coordinators, and social workers. Together, we give all the children we care for and their families the most comprehensive care. We strive to understand each child’s cancer as much as we can, to tailor therapy to their needs, to predict the risk of the cancer coming back, and to counsel families who may have an inherited risk of developing cancer. We work to support each child and family through their journey. We want to make a difficult and frightening experience as bearable as possible. At the end of the day, we are only successful if every patient and family feel they have received the best care.
A pediatric hematologist-oncologist is a doctor who treats cancers of the blood in children and adolescents. This doctor is a hematologist (HEE-muh-TAH-loh-jist) who diagnoses and treats blood disorders. They also are an oncologist (cancer doctor).
My Specialties
- Pediatric Acute and Chronic Leukemias
- Pediatric Lymphoma
- Histiocytosis
- Precision Medicine in Pediatric Oncology
Education
- MD, University of Cagliari, Italy
Residencies
- Pediatrics - St. Vincent's Hospital and Medical Center, New York Medical College
Fellowships
- Pediatric Hematology and Oncology - NewYork-Presbyterian/Columbia University Medical Center
Board Certifications
- Pediatrics
- Pediatric Hematology-Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Sulis sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Sulis
- A Phase 1 Study of Selinexor and Venetoclax with Chemotherapy in Children, Teens, and Young Adults with Acute Leukemia
- A Phase 3 Study of Standard Chemotherapy with or without Venetoclax in Children and Adolescents with Relapsed Acute Myeloid Leukemia
- Clinical Trials Co-Investigated by Dr. Sulis
- A Phase 1 Study of Tagraxofusp With or Without Chemotherapy in Young People With Hematologic Cancers
- A Phase 2 Study of Cobimetinib in People With Langerhans Cell Histiocytosis and Other Histiocytic Disorders
Read more
- A Phase 3 Study of Inotuzumab Ozogamicin and Standard Chemotherapy for Newly Diagnosed High-Risk B-Cell Acute Lymphocytic Leukemia, Mixed Acute Leukemia, and Disseminated B-LLy
- A Phase I Study of MRX-2843 in Adolescents and Young Adults with Recurrent or Persistent Acute Leukemias
- A Phase III Study of Nivolumab in Combination with Chemo-Immunotherapy to Treat Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Sulis’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Maria Luisa Sulis discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].